Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Amphastar Pharmaceuticals, Inc. (AMPH)
USD19.35
+0.54 (+2.87%)
US NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
11570 6th Street 91730
Rancho Cucamonga, CA, US
Rancho Cucamonga, CA, US
CEO
Yongfeng Zhang
Website
amphastar.com
IPO
2014-06-25
CIK 1297184 ISIN US03209R1032
Description
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD19.35
+0.54 (+2.87%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
618.0K
Beta
0.89
Float Shares
33.90M
Free Float %
76.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.15% | -5.81% | -18.07% | -38.60% | -33.64% | -34.65% | -26.72% | -58.09% | -10.53% | +34.82% | +100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Hold
Price Targets & DCF
Current price
19.35
Low
21.00
+8.6%
Consensus
24.33
+25.8%
Median
22.00
+13.7%
High
30.00
+55.1%
DCF (Unlevered)
80.69
+317.1%
DCF (Levered)
91.62
+373.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
29% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | -1 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
22.00
+13.7%
|
| Last Quarter | 1 |
22.00
+13.7%
|
| Last Year | 2 |
26.00
+34.4%
|
| All Time | 6 |
42.67
+120.6%
|
Quality scores
Altman Z-Score
2.16
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-1.7% Q1'26: +0.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-33.7% Q1'26: -72.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+4.5% Q1'26: +22.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+20.7% ★ Q1'26: +8.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.2% ★ Q1'26: +3.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-7.4% ★ Q1'26: -6.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.40× Q1'26: 12.59× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 5 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
251.52M
est: 239.02M (+5.2%)
|
255.17M
est: 247.28M (+3.2%)
|
240.18M
est: 239.95M (+0.1%)
|
294.67M
est: 283.08M (+4.1%)
|
322.36M
est: 320.83M (+0.5%)
|
349.85M
est: 342.50M (+2.1%)
|
437.77M
est: 428.50M (+2.2%)
|
498.99M
est: 491.21M (+1.6%)
|
644.40M
est: 676.21M (-4.7%)
|
731.97M
est: 734.23M (-0.3%)
|
719.89M
est: 725.56M (-0.8%)
|
752.12M
740.24M – 763.99M
+3.7% YoY
|
794.72M
789.25M – 800.19M
+5.7% YoY
|
822.86M
822.07M – 823.65M
+3.5% YoY
|
881.00M
865.17M – 895.08M
+7.1% YoY
|
905.00M
888.73M – 919.47M
+2.7% YoY
|
| EBITDA |
3.88M
est: 66.25M (-94.2%)
|
30.53M
est: 68.54M (-55.4%)
|
11.90M
est: 66.50M (-82.1%)
|
6.83M
est: 78.46M (-91.3%)
|
81.47M
est: 88.92M (-8.4%)
|
30.19M
est: 94.93M (-68.2%)
|
111.56M
est: 118.76M (-6.1%)
|
146.16M
est: 136.14M (+7.4%)
|
240.29M
est: 141.52M (+69.8%)
|
277.31M
est: 153.67M (+80.5%)
|
149.11M
est: 151.85M (-1.8%)
|
157.41M
154.93M – 159.90M
+3.7% YoY
|
166.33M
165.18M – 167.47M
+5.7% YoY
|
172.22M
172.05M – 172.38M
+3.5% YoY
|
184.39M
181.07M – 187.33M
+7.1% YoY
|
189.41M
186.00M – 192.44M
+2.7% YoY
|
| EBIT |
-9.38M
est: 50.37M (-118.6%)
|
15.97M
est: 52.11M (-69.4%)
|
2.08M
est: 50.56M (-95.9%)
|
-9.68M
est: 59.65M (-116.2%)
|
60.35M
est: 67.60M (-10.7%)
|
5.01M
est: 72.17M (-93.1%)
|
85.02M
est: 90.29M (-5.8%)
|
117.89M
est: 103.51M (+13.9%)
|
198.52M
est: 171.39M (+15.8%)
|
220.11M
est: 186.10M (+18.3%)
|
149.11M
est: 183.90M (-18.9%)
|
190.64M
187.62M – 193.64M
+3.7% YoY
|
201.43M
200.05M – 202.82M
+5.7% YoY
|
208.57M
208.37M – 208.77M
+3.5% YoY
|
223.30M
219.29M – 226.87M
+7.1% YoY
|
229.39M
225.26M – 233.05M
+2.7% YoY
|
| Net Income |
-2.79M
est: -10.31M (+73.0%)
|
10.53M
est: 24.38M (-56.8%)
|
4.51M
est: 16.14M (-72.1%)
|
-5.74M
est: 10.41M (-155.1%)
|
48.94M
est: 18.13M (+169.9%)
|
1.40M
est: 30.86M (-95.5%)
|
62.12M
est: 68.37M (-9.1%)
|
91.39M
est: 85.38M (+7.0%)
|
137.55M
est: 154.69M (-11.1%)
|
159.52M
est: 189.11M (-15.6%)
|
98.09M
est: 165.52M (-40.7%)
|
142.99M
138.23M – 147.76M
-13.6% YoY
|
162.55M
158.03M – 167.08M
+13.7% YoY
|
169.98M
166.22M – 173.74M
+4.6% YoY
|
145.61M
142.21M – 148.64M
-14.3% YoY
|
144.65M
141.27M – 147.65M
-0.7% YoY
|
| SGA |
46.97M
est: 34.95M (+34.4%)
|
47.30M
est: 36.15M (+30.8%)
|
50.92M
est: 35.08M (+45.1%)
|
58.04M
est: 41.39M (+40.2%)
|
63.11M
est: 46.91M (+34.5%)
|
65.16M
est: 50.08M (+30.1%)
|
68.92M
est: 62.65M (+10.0%)
|
66.59M
est: 71.82M (-7.3%)
|
80.39M
est: 98.06M (-18.0%)
|
94.52M
est: 106.48M (-11.2%)
|
129.81M
est: 105.22M (+23.4%)
|
109.07M
107.35M – 110.79M
+3.7% YoY
|
115.25M
114.46M – 116.04M
+5.7% YoY
|
119.33M
119.22M – 119.45M
+3.5% YoY
|
127.76M
125.47M – 129.81M
+7.1% YoY
|
131.24M
128.88M – 133.34M
+2.7% YoY
|
| EPS |
-0.06
est: -0.20 (+68.7%)
|
0.23
est: 0.47 (-50.9%)
|
0.10
est: 0.31 (-67.7%)
|
-0.12
est: 0.20 (-160.0%)
|
1.04
est: 0.35 (+198.6%)
|
0.03
est: 0.59 (-95.0%)
|
1.30
est: 1.31 (-1.0%)
|
1.88
est: 1.64 (+14.6%)
|
2.85
est: 3.20 (-11.0%)
|
3.29
est: 3.87 (-15.0%)
|
2.10
est: 3.44 (-38.9%)
|
2.97
2.87 – 3.06
-13.7% YoY
|
3.37
3.28 – 3.47
+13.7% YoY
|
3.53
3.45 – 3.60
+4.7% YoY
|
3.02
2.95 – 3.08
-14.4% YoY
|
3.00
2.93 – 3.06
-0.7% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-21 | Jefferies | Buy | Hold | Downgrade |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
130.84M
OE per share TTM
2.77
Owner's Yield
12.01%
Maintenance CapEx ratio
142.45%
Maint CapEx / Avg PPE
56.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
51
Total invested
32.66M
Insider transactions (90d)
0
Beneficial owners (>5%)
19
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jack Yongfeng Zhang | 12.83M | 25.50% | 3.86M | 8.98M | 3.86M | 8.98M | IN | People’s Republic of China | 2022-02-11 | ↗ |
| 2 | Mary Ziping Luo | 12.83M | 25.50% | 2.14M | 10.69M | 2.14M | 10.69M | IN | of America | 2022-02-11 | ↗ |
| 3 | Applied Physics & Chemistry Laboratories, Inc. | 7.46M | 16.20% | 7.46M | — | 7.46M | — | CO | California | 2018-02-09 | ↗ |
| 4 | (1) BlackRock, Inc. | 7.16M | 15.00% | 6.87M | — | 7.16M | — | HC | Delaware | 2022-01-28 | ↗ |
| 5 | 33-4234397 | 7.03M | 15.00% | 7.03M | — | 7.03M | — | CO | California | 2020-02-14 | ↗ |
| 6 | Applied Physics & Chemistry Laboratories, Inc. | 7.03M | 14.80% | 7.03M | — | 7.03M | — | CO | — | 2021-02-12 | ↗ |
| 7 | Federated Hermes, Inc. | 3.46M | 7.24% | 3.46M | — | 3.46M | — | HC | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 8 | J. Christopher Donahue | 3.46M | 7.24% | — | 3.46M | — | 3.46M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 9 | Rhodora J. Donahue | 3.46M | 7.24% | — | 3.46M | — | 3.46M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 10 | Thomas R. Donahue | 3.46M | 7.24% | — | 3.46M | — | 3.46M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 11 | Voting Shares Irrevocable Trust | 3.46M | 7.24% | 3.46M | — | 3.46M | — | OO | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 12 | The Vanguard Group - 23-1945930 | 2.47M | 5.16% | — | 42.7K | 2.40M | 71.0K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 13 | Consonance Capital Opportunity Fund Management LP | 2.18M | 1.75% | — | 2.18M | — | — | IA, PN | Delaware USA | 2021-02-17 | ↗ |
| 14 | Broadfin Capital, LLC | 2.13M | 4.80% | — | 2.13M | — | 2.13M | IA, OO | Delaware | 2015-02-17 | ↗ |
| 15 | Broadfin Healthcare Master Fund, Ltd. | 2.13M | 4.80% | — | 2.13M | — | 2.13M | CO | Delaware | 2015-02-17 | ↗ |
| 16 | Kevin Kotler | 2.13M | 4.80% | — | 2.13M | — | 2.13M | HC, IN | Delaware | 2015-02-17 | ↗ |
| 17 | Consonance Capital Management LP | — | 0.00% | — | — | — | — | IA, PN | — | 2022-02-14 | ↗ |
| 18 | Consonance Capman GP LLC | — | 0.00% | — | — | — | — | HC, OO | — | 2022-02-14 | ↗ |
| 19 | Mitchell Blutt | — | 0.00% | — | — | — | — | HC, IN | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
51
-185 vs prev Q
New positions
8
Closed positions
191
Increased
19
Reduced
23
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 5.46M -23.0K (-0.4%) | 146.27M +96.0K (+0.1%) | 11.75% +0.070 pp | 0.00% 0.000 pp | USD48.28 -44.5% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 2.61M -22.9K (-0.9%) | 69.85M -270.7K (-0.4%) | 5.61% +0.008 pp | 0.00% +0.000 pp | USD20.78 +28.9% | 46 qtrs — |
| 3 | TD ASSET MANAGEMENT INC | 1.96M +31.2K (+1.6%) | 52.57M +1.1M (+2.1%) | 4.22% +0.109 pp | 0.04% +0.001 pp | USD45.68 -41.4% | 12 qtrs — |
| 4 | DIMENSIONAL FUND ADVISORS LP | 1.80M +44.0K (+2.5%) | 48.20M +1.4M (+3.0%) | 3.87% +0.133 pp | 0.01% +0.000 pp | USD22.40 +19.6% | 41 qtrs — |
| 5 | STATE STREET CORP | 1.53M +31.0K (+2.1%) | 41.02M +1.0M (+2.6%) | 3.30% +0.100 pp | 0.00% +0.000 pp | USD23.53 +13.8% | 46 qtrs — |
| 6 | FULLER & THALER ASSET MANAGEMENT, INC. | 1.39M +40.5K (+3.0%) | 37.34M +1.3M (+3.5%) | 3.00% +0.117 pp | 0.13% +0.004 pp | USD37.54 -28.7% | 23 qtrs — |
| 7 | MARSHALL WACE, LLP | 1.24M +363.2K (+41.6%) | 33.13M +9.8M (+42.2%) | 2.66% +0.801 pp | 0.03% +0.007 pp | USD34.38 -22.1% | 7 qtrs — |
| 8 | EPOCH INVESTMENT PARTNERS, INC. | 1.13M -7.4K (-0.7%) | 30.17M -50.8K (-0.2%) | 2.42% +0.009 pp | 0.17% +0.005 pp | USD48.58 -44.9% | 11 qtrs — |
| 9 | BOSTON TRUST WALDEN CORP | 1.09M -85.8K (-7.3%) | 29.12M -2.1M (-6.9%) | 2.34% -0.159 pp | 0.22% -0.010 pp | USD40.61 -34.1% | 6 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 886.8K -35.8K (-3.9%) | 23.75M -836.7K (-3.4%) | 1.91% -0.057 pp | 0.00% 0.000 pp | USD23.86 +12.2% | 46 qtrs — |
| 11 | AMERICAN CENTURY COMPANIES INC | 665.3K +376.8K (+130.6%) | 17.82M +10.1M (+131.7%) | 1.43% +0.817 pp | 0.01% +0.005 pp | USD33.05 -19.0% | 19 qtrs — |
| 12 | MORGAN STANLEY | 591.6K +17.0K (+2.9%) | 15.84M +528.7K (+3.5%) | 1.27% +0.049 pp | 0.00% +0.000 pp | USD29.12 -8.0% | 46 qtrs — |
| 13 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 559.4K +167.1K (+42.6%) | 14.98M +4.5M (+43.3%) | 1.20% +0.368 pp | 0.01% +0.002 pp | USD26.15 +2.4% | 3 qtrs — |
| 14 | D. E. SHAW & CO., INC. | 557.1K +39.8K (+7.7%) | 14.92M +1.1M (+8.2%) | 1.20% +0.097 pp | 0.01% +0.000 pp | USD25.57 +4.7% | 6 qtrs — |
| 15 | GOLDMAN SACHS GROUP INC | 556.7K +315.5K (+130.8%) | 14.91M +8.5M (+131.9%) | 1.20% +0.684 pp | 0.00% +0.001 pp | USD34.79 -23.0% | 46 qtrs — |
| 16 | RENAISSANCE TECHNOLOGIES LLC | 544.7K -42.2K (-7.2%) | 14.59M -1.1M (-6.7%) | 1.17% -0.078 pp | 0.02% +0.002 pp | USD30.60 -12.5% | 33 qtrs — |
| 17 | INVESCO LTD. | 501.4K +111.8K (+28.7%) | 13.43M +3.0M (+29.3%) | 1.08% +0.249 pp | 0.00% +0.000 pp | USD25.49 +5.1% | 40 qtrs — |
| 18 | SYSTEMATIC FINANCIAL MANAGEMENT LP | 435.6K +12.5K (+2.9%) | 11.66M +388.9K (+3.4%) | 0.94% +0.036 pp | 0.28% +0.001 pp | USD32.73 -18.2% | 5 qtrs — |
| 19 | HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | 402.6K +76.4K (+23.4%) | 10.78M +2.1M (+24.0%) | 0.87% +0.172 pp | 0.03% +0.005 pp | USD37.19 -28.0% | 6 qtrs — |
| 20 | NORTHERN TRUST CORP | 371.4K -28.1K (-7.0%) | 9.95M -700.0K (-6.6%) | 0.80% -0.052 pp | 0.00% 0.000 pp | USD25.41 +5.4% | 46 qtrs — |
| 21 | ROYCE & ASSOCIATES LP | 352.3K -14.0K (-3.8%) | 9.43M -328.0K (-3.4%) | 0.76% -0.022 pp | 0.10% -0.002 pp | USD28.11 -4.7% | 7 qtrs — |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 350.7K -5.7K (-1.6%) | 9.39M -106.4K (-1.1%) | 0.75% -0.005 pp | 0.00% 0.000 pp | USD25.79 +3.8% | 45 qtrs — |
| 23 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 323.5K +11.2K (+3.6%) | 8.66M +340.9K (+4.1%) | 0.70% +0.031 pp | 0.18% +0.004 pp | USD25.68 +4.3% | 3 qtrs — |
| 24 | CLARK CAPITAL MANAGEMENT GROUP, INC. | 317.5K +33.8K (+11.9%) | 8.50M +942.3K (+12.5%) | 0.68% +0.079 pp | 0.05% +0.005 pp | USD26.66 +0.5% | 2 qtrs — |
| 25 | VICTORY CAPITAL MANAGEMENT INC | 305.2K +93.4K (+44.1%) | 8.17M +2.5M (+44.8%) | 0.66% +0.206 pp | 0.00% +0.001 pp | USD32.79 -18.3% | 26 qtrs — |
| 26 | MILLENNIUM MANAGEMENT LLC | 290.7K -407.1K (-58.3%) | 7.78M -10.8M (-58.1%) | 0.63% -0.861 pp | 0.00% -0.005 pp | USD31.48 -14.9% | 23 qtrs — |
| 27 | BANK OF NEW YORK MELLON CORP | 259.1K -8.8K (-3.3%) | 6.94M -200.0K (-2.8%) | 0.56% -0.013 pp | 0.00% 0.000 pp | USD21.55 +24.3% | 46 qtrs — |
| 28 | UBS GROUP AG | 256.6K -55.7K (-17.8%) | 6.87M -1.4M (-17.4%) | 0.55% -0.113 pp | 0.00% 0.000 pp | USD30.45 -12.1% | 45 qtrs — |
| 29 | BRIDGE CITY CAPITAL, LLC | 235.5K +99.2K (+72.8%) | 6.31M +2.7M (+73.7%) | 0.51% +0.217 pp | 1.85% +0.884 pp | USD34.09 -21.4% | 11 qtrs — |
| 30 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 231.3K -61.1K (-20.9%) | 6.19M -1.6M (-20.5%) | 0.50% -0.125 pp | 0.02% -0.004 pp | USD34.47 -22.3% | 16 qtrs — |
| 31 | CITADEL ADVISORS LLC | 228.7K +1.9K (+0.9%) | 6.13M +81.7K (+1.4%) | 0.49% +0.009 pp | 0.00% +0.000 pp | USD32.30 -17.1% | 29 qtrs — |
| 32 | PRINCIPAL FINANCIAL GROUP INC | 218.0K +12.3K (+6.0%) | 5.84M +356.0K (+6.5%) | 0.47% +0.031 pp | 0.00% +0.000 pp | USD21.98 +21.8% | 38 qtrs — |
| 33 | JANE STREET GROUP, LLC | 217.5K +69.1K (+46.5%) | 5.83M +1.9M (+47.2%) | 0.47% +0.152 pp | 0.00% +0.000 pp | USD27.55 -2.8% | 17 qtrs — |
| 34 | DENALI ADVISORS LLC | 211.8K +76.8K (+56.9%) | 5.67M +2.1M (+57.6%) | 0.46% +0.168 pp | 0.63% +0.223 pp | USD26.70 +0.3% | 2 qtrs — |
| 35 | PACER ADVISORS, INC. | 177.7K +171.7K (+2,864.4%) | 4.76M +4.6M (+2,878.8%) | 0.38% +0.370 pp | 0.01% +0.012 pp | USD27.13 -1.3% | 15 qtrs — |
| 36 | EMPOWERED FUNDS, LLC | 165.9K +16.1K (+10.8%) | 4.44M +451.0K (+11.3%) | 0.36% +0.038 pp | 0.04% -0.005 pp | USD24.77 +8.1% | 3 qtrs — |
| 37 | JPMORGAN CHASE & CO | 158.6K -94.6K (-37.4%) | 4.25M -2.5M (-37.0%) | 0.34% -0.198 pp | 0.00% 0.000 pp | USD27.97 -4.3% | 46 qtrs — |
| 38 | FIRST TRUST ADVISORS LP | 140.3K -10.1K (-6.7%) | 3.76M -251.2K (-6.3%) | 0.30% -0.019 pp | 0.00% 0.000 pp | USD26.27 +1.9% | 13 qtrs — |
| 39 | AMERIPRISE FINANCIAL INC | 133.7K +3.9K (+3.0%) | 3.58M +120.6K (+3.5%) | 0.29% +0.011 pp | 0.00% +0.000 pp | USD24.09 +11.2% | 39 qtrs — |
| 40 | LAM GROUP, INC. | 130.8K +— (+0.0%) | 3.50M +17.0K (+0.5%) | 0.28% +0.003 pp | 2.00% -0.156 pp | USD28.74 -6.8% | 13 qtrs — |
| 41 | NORDEA INVESTMENT MANAGEMENT AB | 129.1K -24.2K (-15.8%) | 3.46M -631.6K (-15.4%) | 0.28% -0.049 pp | 0.00% -0.001 pp | USD24.54 +9.1% | 36 qtrs — |
| 42 | BANK OF AMERICA CORP /DE/ | 128.2K +1.1K (+0.8%) | 3.43M +45.4K (+1.3%) | 0.28% +0.005 pp | 0.00% +0.000 pp | USD38.36 -30.2% | 44 qtrs — |
| 43 | NEW YORK STATE COMMON RETIREMENT FUND | 126.0K +35.8K (+39.7%) | 3.37M +970.4K (+40.4%) | 0.27% +0.079 pp | 0.00% +0.001 pp | USD29.62 -9.6% | 43 qtrs — |
| 44 | ALGERT GLOBAL LLC | 125.1K -267.8K (-68.2%) | 3.35M -7.1M (-68.0%) | 0.27% -0.568 pp | 0.05% -0.123 pp | USD25.75 +4.0% | 6 qtrs — |
| 45 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 122.5K -17.2K (-12.3%) | 3.28M -441.7K (-11.9%) | 0.26% -0.034 pp | 0.01% -0.003 pp | USD33.79 -20.7% | 38 qtrs — |
| 46 | RICE HALL JAMES & ASSOCIATES, LLC | 121.2K -8.2K (-6.3%) | 3.25M -201.8K (-5.9%) | 0.26% -0.015 pp | 0.18% -0.009 pp | USD26.65 +0.5% | 2 qtrs — |
| 47 | BESSEMER GROUP INC | 120.9K +120.7K (+84,438.5%) | 3.24M +3.2M (+80,850.0%) | 0.26% +0.260 pp | 0.01% +0.005 pp | USD26.81 -0.1% | 16 qtrs — |
| 48 | BNP PARIBAS ARBITRAGE, SNC | 120.9K -101.1K (-45.5%) | 3.24M -2.7M (-45.3%) | 0.26% -0.213 pp | 0.00% -0.002 pp | USD26.32 +1.7% | 44 qtrs — |
| 49 | TREXQUANT INVESTMENT LP | 113.7K +113.7K (+100.0%) | 3.04M +3.0M (+100.0%) | 0.24% +0.245 pp | 0.03% +0.027 pp | USD26.78 +0.0% | 17 qtrs — |
| 50 | QUBE RESEARCH & TECHNOLOGIES LTD | 111.4K -129.8K (-53.8%) | 2.98M -3.4M (-53.6%) | 0.24% -0.274 pp | 0.00% -0.004 pp | USD29.58 -9.5% | 16 qtrs — |
| 51 | LSV ASSET MANAGEMENT | 110.3K +37.0K (+50.5%) | 2.95M +1.0M (+51.3%) | 0.24% +0.081 pp | 0.01% +0.002 pp | USD36.68 -27.0% | 19 qtrs — |
| 52 | BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC | 105.4K +105.4K (+100.0%) | 2.82M +2.8M (+100.0%) | 0.23% +0.227 pp | 0.02% +0.019 pp | USD26.78 +0.0% | 1 qtrs NEW |
| 53 | TWO SIGMA INVESTMENTS, LP | 98.7K +— (+0.0%) | 2.64M +12.8K (+0.5%) | 0.21% +0.002 pp | 0.00% 0.000 pp | USD41.36 -35.3% | 11 qtrs — |
| 54 | SG AMERICAS SECURITIES, LLC | 93.5K +93.5K (+100.0%) | 2.50M +2.5M (+100.0%) | 0.20% +0.201 pp | 0.00% +0.003 pp | USD26.78 +0.0% | 3 qtrs — |
| 55 | QUANTEDGE CAPITAL PTE LTD | 91.7K +46.6K (+103.3%) | 2.46M +1.3M (+104.3%) | 0.20% +0.101 pp | 1.17% +0.513 pp | USD26.72 +0.2% | 2 qtrs — |
| 56 | LEGAL & GENERAL GROUP PLC | 90.7K -6.9K (-7.1%) | 2.43M -171.7K (-6.6%) | 0.20% -0.013 pp | 0.00% +0.000 pp | USD25.19 +6.3% | 43 qtrs — |
| 57 | O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 87.2K +18.1K (+26.2%) | 2.33M +494.4K (+26.9%) | 0.19% +0.041 pp | 0.01% +0.002 pp | USD24.97 +7.2% | 3 qtrs — |
| 58 | RAYMOND JAMES FINANCIAL INC | 84.5K -33.7K (-28.5%) | 2.26M -888.0K (-28.2%) | 0.18% -0.070 pp | 0.00% 0.000 pp | USD26.55 +0.9% | 5 qtrs — |
| 59 | RHUMBLINE ADVISERS | 82.4K -7.7K (-8.6%) | 2.21M -195.5K (-8.1%) | 0.18% -0.015 pp | 0.00% 0.000 pp | USD21.72 +23.3% | 43 qtrs — |
| 60 | BALYASNY ASSET MANAGEMENT L.P. | 77.5K -64.4K (-45.4%) | 2.07M -1.7M (-45.1%) | 0.17% -0.136 pp | 0.00% -0.002 pp | USD26.63 +0.6% | 4 qtrs — |
| 61 | NUVEEN, LLC | 76.1K -1.6K (-2.1%) | 2.04M -32.8K (-1.6%) | 0.16% -0.002 pp | 0.00% +0.000 pp | USD28.99 -7.6% | 4 qtrs — |
| 62 | BARCLAYS PLC | 75.3K +863.0 (+1.2%) | 2.02M -1.6M (-44.2%) | 0.16% +0.004 pp | 0.00% 0.000 pp | USD41.80 -35.9% | 45 qtrs — |
| 63 | SWISS NATIONAL BANK | 72.6K +— (+0.0%) | 1.94M +9.4K (+0.5%) | 0.16% +0.002 pp | 0.00% +0.000 pp | USD20.38 +31.4% | 43 qtrs — |
| 64 | AQR CAPITAL MANAGEMENT LLC | 67.7K +5.5K (+8.9%) | 1.81M +155.6K (+9.4%) | 0.15% +0.013 pp | 0.00% 0.000 pp | USD31.15 -14.0% | 42 qtrs — |
| 65 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 67.0K +27.4K (+69.3%) | 1.79M +739.0K (+70.1%) | 0.14% +0.060 pp | 0.03% +0.011 pp | USD24.52 +9.2% | 3 qtrs — |
| 66 | CX INSTITUTIONAL | 64.1K +807.0 (+1.3%) | 1.72M +30.0K (+1.8%) | 0.14% +0.003 pp | 0.05% +0.000 pp | USD24.87 +7.7% | 4 qtrs — |
| 67 | INTECH INVESTMENT MANAGEMENT LLC | 63.2K +12.1K (+23.6%) | 1.69M +329.9K (+24.2%) | 0.14% +0.027 pp | 0.02% +0.003 pp | USD33.71 -20.6% | 7 qtrs — |
| 68 | CIBC WORLD MARKET INC. | 62.2K +62.2K (+100.0%) | 1.67M +1.7M (+100.0%) | 0.13% +0.134 pp | 0.00% +0.003 pp | USD26.78 +0.0% | 1 qtrs NEW |
| 69 | ALLIANCEBERNSTEIN L.P. | 60.6K +10.0K (+19.8%) | 1.62M +274.4K (+20.3%) | 0.13% +0.023 pp | 0.00% +0.000 pp | USD36.65 -26.9% | 44 qtrs — |
| 70 | STEEL PEAK WEALTH MANAGEMENT LLC | 55.7K +— (+0.0%) | 1.49M +7.2K (+0.5%) | 0.12% +0.001 pp | 0.05% -0.001 pp | USD28.99 -7.6% | 4 qtrs — |
| 71 | UBS ASSET MANAGEMENT AMERICAS INC | 55.2K +897.0 (+1.7%) | 1.48M +31.1K (+2.1%) | 0.12% +0.003 pp | 0.00% +0.000 pp | USD31.16 -14.1% | 44 qtrs — |
| 72 | ASSETMARK, INC | 54.4K -2.1K (-3.8%) | 1.46M -49.6K (-3.3%) | 0.12% -0.003 pp | 0.00% 0.000 pp | USD32.97 -18.8% | 14 qtrs — |
| 73 | CREATIVE PLANNING | 51.7K -3.5K (-6.3%) | 1.38M -85.3K (-5.8%) | 0.11% -0.006 pp | 0.00% 0.000 pp | USD26.00 +3.0% | 5 qtrs — |
| 74 | XTX TOPCO LTD | 48.6K +48.6K (+100.0%) | 1.30M +1.3M (+100.0%) | 0.10% +0.105 pp | 0.03% +0.034 pp | USD26.78 +0.0% | 1 qtrs NEW |
| 75 | PRUDENTIAL FINANCIAL INC | 47.2K -226.0 (-0.5%) | 1.26M +113.0 (+0.0%) | 0.10% +0.001 pp | 0.00% +0.000 pp | USD29.61 -9.6% | 38 qtrs — |
| 76 | WELLS FARGO & COMPANY/MN | 45.3K +16.6K (+57.6%) | 1.21M +447.0K (+58.3%) | 0.10% +0.036 pp | 0.00% +0.000 pp | USD35.25 -24.0% | 45 qtrs — |
| 77 | SUMMERHAVEN INVESTMENT MANAGEMENT, LLC | 38.2K +— (+0.0%) | 1.02M +5.0K (+0.5%) | 0.08% +0.001 pp | 0.58% -0.012 pp | USD26.65 +0.5% | 2 qtrs — |
| 78 | PRICE T ROWE ASSOCIATES INC /MD/ | 36.8K -238.4K (-86.6%) | 986.0K -6.4M (-86.6%) | 0.08% -0.507 pp | 0.00% -0.001 pp | USD33.94 -21.1% | 15 qtrs — |
| 79 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 35.8K -81.0 (-0.2%) | 958.7K +2.5K (+0.3%) | 0.08% +0.001 pp | 0.00% +0.000 pp | USD16.71 +60.3% | 46 qtrs — |
| 80 | POLARIS CAPITAL MANAGEMENT, LLC | 35.5K +22.4K (+171.2%) | 951.5K +602.4K (+172.6%) | 0.08% +0.049 pp | 0.08% +0.056 pp | USD29.42 -9.0% | 5 qtrs — |
| 81 | CAMPBELL & CO INVESTMENT ADVISER LLC | 30.7K -13.4K (-30.4%) | 821.7K -352.7K (-30.0%) | 0.07% -0.028 pp | 0.04% -0.049 pp | USD31.98 -16.3% | 8 qtrs — |
| 82 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 30.2K +— (+0.0%) | 809.0K -4.0K (-0.5%) | 0.07% +0.001 pp | 0.00% +0.000 pp | USD29.49 -9.2% | 43 qtrs — |
| 83 | CANADA PENSION PLAN INVESTMENT BOARD | 29.8K +9.1K (+44.0%) | 798.0K +246.4K (+44.7%) | 0.06% +0.020 pp | 0.00% +0.000 pp | USD26.74 +0.1% | 5 qtrs — |
| 84 | DEUTSCHE BANK AG\ | 29.6K +1.2K (+4.1%) | 791.5K +34.8K (+4.6%) | 0.06% +0.003 pp | 0.00% +0.000 pp | USD37.54 -28.7% | 45 qtrs — |
| 85 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 29.1K +29.1K (+100.0%) | 785.3K +785.3K (+100.0%) | 0.06% +0.063 pp | 0.00% +0.001 pp | USD26.78 +0.0% | 1 qtrs NEW |
| 86 | ENVESTNET ASSET MANAGEMENT INC | 28.8K +6.8K (+31.2%) | 771.9K +186.2K (+31.8%) | 0.06% +0.015 pp | 0.00% +0.000 pp | USD26.68 +0.4% | 12 qtrs — |
| 87 | ILLUMINE INVESTMENT MANAGEMENT, LLC | 28.3K +651.0 (+2.4%) | 758.6K +21.0K (+2.9%) | 0.06% +0.002 pp | 0.55% +0.028 pp | USD33.67 -20.5% | 5 qtrs — |
| 88 | CITIGROUP INC | 28.3K +8.5K (+42.7%) | 757.3K +229.3K (+43.4%) | 0.06% +0.019 pp | 0.00% +0.000 pp | USD35.27 -24.1% | 46 qtrs — |
| 89 | STATE OF ALASKA, DEPARTMENT OF REVENUE | 27.9K +7.1K (+34.3%) | 747.0K +194.0K (+35.1%) | 0.06% +0.016 pp | 0.01% +0.002 pp | USD21.91 +22.2% | 37 qtrs — |
| 90 | GOTHAM ASSET MANAGEMENT, LLC | 27.8K +12.4K (+81.0%) | 744.5K +335.1K (+81.8%) | 0.06% +0.027 pp | 0.00% +0.001 pp | USD34.22 -21.7% | 16 qtrs — |
| 91 | FREESTONE GROVE PARTNERS LP | 27.6K +27.6K (+100.0%) | 738.9K +738.9K (+100.0%) | 0.06% +0.059 pp | 0.01% +0.005 pp | USD26.78 +0.0% | 1 qtrs NEW |
| 92 | LEGATO CAPITAL MANAGEMENT LLC | 26.6K -9.5K (-26.3%) | 712.1K -248.9K (-25.9%) | 0.06% -0.020 pp | 0.06% -0.043 pp | USD39.96 -33.0% | 11 qtrs — |
| 93 | ARKADIOS WEALTH ADVISORS | 26.3K -9.7K (-27.0%) | 704.4K -255.2K (-26.6%) | 0.06% -0.020 pp | 0.01% -0.009 pp | USD36.31 -26.2% | 7 qtrs — |
| 94 | FRANKLIN RESOURCES INC | 26.0K +16.5K (+173.4%) | 697.5K +443.6K (+174.8%) | 0.06% +0.036 pp | 0.00% +0.000 pp | USD26.73 +0.2% | 20 qtrs — |
| 95 | ADVISOR OS, LLC | 25.4K +— (+0.0%) | 680.3K +3.3K (+0.5%) | 0.05% +0.001 pp | 0.05% -0.004 pp | USD43.44 -38.4% | 8 qtrs — |
| 96 | THRIVENT FINANCIAL FOR LUTHERANS | 24.3K -1.5K (-5.9%) | 651.0K -37.0K (-5.4%) | 0.05% -0.003 pp | 0.00% 0.000 pp | USD42.48 -37.0% | 38 qtrs — |
| 97 | FEDERATED HERMES, INC. | 23.5K +23.5K (+100.0%) | 630.3K +630.3K (+100.0%) | 0.05% +0.051 pp | 0.00% +0.001 pp | USD26.78 +0.0% | 46 qtrs — |
| 98 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 23.0K -351.0 (-1.5%) | 615.0K -7.0K (-1.1%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD27.20 -1.5% | 38 qtrs — |
| 99 | METLIFE INVESTMENT MANAGEMENT, LLC | 21.1K -2.0K (-8.7%) | 564.4K -51.0K (-8.3%) | 0.05% -0.004 pp | 0.00% 0.000 pp | USD28.29 -5.3% | 33 qtrs — |
| 100 | ILLINOIS MUNICIPAL RETIREMENT FUND | 20.9K +166.0 (+0.8%) | 560.1K +7.1K (+1.3%) | 0.05% +0.001 pp | 0.01% +0.000 pp | USD45.10 -40.6% | 10 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 140 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.12% | 5.28M | 0.35% |
| 2 | ETC 6 Meridian Small Cap Equity ETF SIXS | 0.99% | 1.05M | 0.52% |
| 3 | Acquirers Small and Micro Deep Value ETF DEEP | 0.85% | 232.0K | 0.80% |
| 4 | Distillate Small/Mid Cash Flow ETF DSMC | 0.49% | 640.6K | 0.55% |
| 5 | Pacer US Small Cap Cash Cows Growth Leaders ETF CAFG | 0.40% | 121.1K | 0.59% |
| 6 | First Trust Small Cap Core AlphaDEX Fund FYX | 0.30% | 4.02M | 0.58% |
| 7 | Invesco S&P SmallCap Health Care ETF PSCH | 0.28% | 454.1K | 0.29% |
| 8 | VictoryShares Small Cap Free Cash Flow ETF SFLO | 0.24% | 1.52M | 0.56% |
| 9 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.23% | 54.2K | 1.22% |
| 10 | iShares US Small Cap Value Factor ETF SVAL | 0.22% | 434.7K | 0.20% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
3.00
Bullish
Buys
10
Sells
20
Shares acquired
1.18M
Shares disposed
71.0K
Cash buys
—
Cash sales
—
Net activity
+1,112,873
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-15 | Zhou Rong | Officer | F-InKind | D | Common Stock | 1,225 | 18.18 | 22.3K | 171,554 | D | ↗ |
| 2026-03-15 | Zhang Jack Y. | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 9,784 | 18.18 | 177.9K | 2,990,052 | D | ↗ |
| 2026-03-15 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 1,973 | 18.18 | 35.9K | 175,063 | D | ↗ |
| 2026-03-15 | Liawatidewi Yakob | Director / Officer | F-InKind | D | Common Stock | 1,033 | 18.18 | 18.8K | 121,892 | D | ↗ |
| 2026-03-10 | Zhou Rong | Officer | F-InKind | D | Common Stock | 2,215 | 18.91 | 41.9K | 172,779 | D | ↗ |
| 2026-03-10 | Zhang Jack Y. | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 4,395 | 18.91 | 83.1K | 1,248,033 | I | ↗ |
| 2026-03-10 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 3,297 | 18.91 | 62.3K | 177,036 | D | ↗ |
| 2026-03-10 | Liawatidewi Yakob | Director / Officer | F-InKind | D | Common Stock | 1,870 | 18.91 | 35.4K | 122,925 | D | ↗ |
| 2026-03-09 | Zhou Rong | Officer | A-Award | A | Common Srock | 39,432 | 0.00 | — | 174,994 | D | ↗ |
| 2026-03-09 | Zhang Jack Y. | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 149,472 | 19.21 | 2.87M | 149,472 | I | ↗ |
| 2026-03-09 | PETERS WILLIAM J | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 121,071 | 19.21 | 2.33M | 121,071 | D | ↗ |
| 2026-03-09 | Liawatidewi Yakob | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 73,126 | 19.21 | 1.40M | 73,126 | D | ↗ |
| 2026-03-06 | Zhou Rong | Officer | F-InKind | D | Common Stock | 1,357 | 19.34 | 26.2K | 135,562 | D | ↗ |
| 2026-03-06 | Zhang Jack Y. | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 7,773 | 19.34 | 150.3K | 2,834,117 | D | ↗ |
| 2026-03-06 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 2,146 | 19.34 | 41.5K | 121,640 | D | ↗ |
| 2026-03-06 | Liawatidewi Yakob | Director / Officer | F-InKind | D | Common Stock | 1,144 | 19.34 | 22.1K | 89,345 | D | ↗ |
| 2026-03-04 | Zhou Rong | Officer | F-InKind | D | Common Stock | 1,124 | 19.96 | 22.4K | 136,919 | D | ↗ |
| 2026-03-04 | Zhang Jack Y. | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 2,432 | 19.96 | 48.5K | 1,183,043 | I | ↗ |
| 2026-03-04 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 1,744 | 19.96 | 34.8K | 123,786 | D | ↗ |
| 2026-03-04 | Liawatidewi Yakob | Director / Officer | F-InKind | D | Common Stock | 965 | 19.96 | 19.3K | 90,489 | D | ↗ |
| 2025-12-17 | Zhou Rong | Officer | M-Exempt | A | Common Stock | 9,787 | 11.33 | 110.9K | 147,830 | D | ↗ |
| 2025-12-12 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 2,426 | 25.92 | 62.9K | 71,368 | D | ↗ |
| 2025-12-11 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 1,737 | 25.69 | 44.6K | 73,794 | D | ↗ |
| 2025-11-25 | PRINS RICHARD K | Director | M-Exempt | A | Common Stock | 4,179 | 16.69 | 69.7K | 39,362 | D | ↗ |
| 2025-11-13 | Petersen Floyd F. | Director | M-Exempt | A | Common Stock | 16,679 | 16.69 | 278.4K | 92,210 | D | ↗ |
| 2025-11-03 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 25.27 | 12.6K | 75,531 | D | ↗ |
| 2025-10-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 27.20 | 13.6K | 76,031 | D | ↗ |
| 2025-09-02 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 30.98 | 15.5K | 76,531 | D | ↗ |
| 2025-08-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 20.83 | 10.4K | 77,031 | D | ↗ |
| 2025-07-18 | Gaugh David Russell | Director | A-Award | A | Stock Option (right to buy) | 13,987 | 20.62 | 288.4K | 13,987 | D | ↗ |
| 2025-07-02 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 23.47 | 11.7K | 77,531 | D | ↗ |
| 2025-06-13 | Zhang Jack Y. | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 200,000 | 13.03 | 2.61M | 2,847,659 | D | ↗ |
| 2025-06-03 | Lee Howard | Director | F-InKind | D | Common Stock | 923 | 26.01 | 24.0K | 151,976 | D | ↗ |
| 2025-06-02 | ZASLOFF MICHAEL A | Director | A-Award | A | Common Stock | 5,122 | 0.00 | — | 29,524 | D | ↗ |
| 2025-06-02 | Petersen Floyd F. | Director | A-Award | A | Stock Option (right to buy) | 11,402 | 25.38 | 289.4K | 11,402 | D | ↗ |
| 2025-06-02 | PRINS RICHARD K | Director | A-Award | A | Common Stock | 5,122 | 0.00 | — | 35,183 | D | ↗ |
| 2025-06-02 | Lee Howard | Director | A-Award | A | Stock Option (right to buy) | 11,402 | 25.38 | 289.4K | 11,402 | D | ↗ |
| 2025-06-02 | Gerst Diane G. | Director | A-Award | A | Stock Option (right to buy) | 11,402 | 25.38 | 289.4K | 11,402 | D | ↗ |
| 2025-06-02 | Deflin Gayle | Director | A-Award | A | Stock Option (right to buy) | 11,402 | 25.38 | 289.4K | 11,402 | D | ↗ |
| 2025-05-19 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 273 | 24.79 | 6.8K | 124,985 | D | ↗ |
| 2025-05-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 24.08 | 12.0K | 73,409 | D | ↗ |
| 2025-04-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 28.38 | 14.2K | 73,909 | D | ↗ |
| 2025-03-17 | Zhou Rong | Officer | F-InKind | D | Common Srock | 1,967 | 27.69 | 54.5K | 137,497 | D | ↗ |
| 2025-03-17 | Zhang Jack Y. | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 7,223 | 27.69 | 200.0K | 1,185,475 | I | ↗ |
| 2025-03-17 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 3,004 | 27.69 | 83.2K | 125,258 | D | ↗ |
| 2025-03-17 | Liawatidewi Yakob | Director / Officer | F-InKind | D | Common Stock | 1,731 | 27.69 | 47.9K | 90,909 | D | ↗ |
| 2025-03-15 | Zhou Rong | Officer | F-InKind | D | Common Stock | 1,222 | 26.66 | 32.6K | 139,464 | D | ↗ |
| 2025-03-15 | Zhang Jack Y. | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 4,115 | 26.66 | 109.7K | 1,192,698 | I | ↗ |
| 2025-03-15 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 1,968 | 26.66 | 52.5K | 128,262 | D | ↗ |
| 2025-03-15 | Liawatidewi Yakob | Director / Officer | F-InKind | D | Common Stock | 1,031 | 26.66 | 27.5K | 92,640 | D | ↗ |
| 2025-03-14 | Zhang Jack Y. | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 162,657 | 26.66 | 4.34M | 1,196,813 | I | ↗ |
| 2025-03-10 | Zhou Rong | Officer | A-Award | A | Common Srock | 24,692 | 0.00 | — | 140,686 | D | ↗ |
| 2025-03-10 | Zhang Jack Y. | Director / Officer / 10% Owner | A-Award | A | Common Stock | 116,226 | 0.00 | — | 2,609,382 | D | ↗ |
| 2025-03-10 | PETERS WILLIAM J | Director / Officer | A-Award | A | Common Stock | 36,747 | 0.00 | — | 130,230 | D | ↗ |
| 2025-03-10 | Liawatidewi Yakob | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 44,253 | 28.41 | 1.26M | 44,253 | D | ↗ |
| 2025-03-06 | Zhou Rong | Officer | F-InKind | D | Common Stock | 1,354 | 28.32 | 38.3K | 115,994 | D | ↗ |
| 2025-03-06 | Zhang Jack Y. | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 9,645 | 28.32 | 273.1K | 2,493,156 | D | ↗ |
| 2025-03-06 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 1,000 | 27.99 | 28.0K | 74,409 | D | ↗ |
| 2025-03-06 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 2,141 | 28.32 | 60.6K | 93,483 | D | ↗ |
| 2025-03-06 | Liawatidewi Yakob | Director / Officer | F-InKind | D | Common Stock | 1,141 | 28.32 | 32.3K | 72,834 | D | ↗ |
| 2025-03-04 | PETERS WILLIAM J | Director / Officer | M-Exempt | A | Common Stock | 7,490 | 13.35 | 100.0K | 101,594 | D | ↗ |
| 2024-12-13 | Zhou Rong | Officer | M-Exempt | A | Common Stock | 8,000 | 11.33 | 90.6K | 126,469 | D | ↗ |
| 2024-12-12 | Zhou Rong | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 7,000 | 11.33 | 79.3K | 17,787 | D | ↗ |
| 2024-12-09 | PRINS RICHARD K | Director | M-Exempt | A | Common Stock | 10,000 | 19.52 | 195.2K | 40,471 | D | ↗ |
| 2024-11-12 | Zhou Rong | Officer | M-Exempt | A | Common Stock | 6,893 | 14.95 | 103.1K | 125,281 | D | ↗ |
| 2024-11-12 | PRINS RICHARD K | Director | M-Exempt | A | Common Stock | 2,500 | 16.69 | 41.7K | 36,471 | D | ↗ |
| 2024-11-11 | Zhang Jack Y. | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 125,000 | 0.00 | — | 2,508,554 | D | ↗ |
| 2024-11-06 | PETERS WILLIAM J | Director / Officer | M-Exempt | A | Common Stock | 7,426 | 13.03 | 96.8K | 101,529 | D | ↗ |
| 2024-11-06 | Liawatidewi Yakob | Director / Officer | M-Exempt | A | Common Stock | 5,214 | 13.03 | 67.9K | 80,152 | D | ↗ |
| 2024-09-13 | Zhou Rong | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 3,000 | 14.95 | 44.9K | 6,893 | — | ↗ |
| 2024-09-13 | Zhang Jack Y. | Director / Officer / 10% Owner | M-Exempt | D | Employee Stock Option (right to buy) | 100,000 | 14.69 | 1.47M | 290,477 | — | ↗ |
| 2024-09-05 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 3,000 | 46.47 | 139.4K | 75,409 | — | ↗ |
| 2024-08-26 | Zhou Rong | Officer | M-Exempt | A | Common Srock | 4,000 | 14.95 | 59.8K | 122,388 | — | ↗ |
| 2024-08-12 | PRINS RICHARD K | Director | M-Exempt | A | Common Stock | 7,182 | 19.52 | 140.2K | 51,072 | — | ↗ |
| 2024-07-31 | PETERS WILLIAM J | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 10,282 | 20.23 | 208.0K | 4,943 | — | ↗ |
| 2024-06-27 | PETERS WILLIAM J | Director / Officer | S-Sale | D | Common Stock | 2,961 | 40.85 | 120.9K | 94,738 | — | ↗ |
| 2024-06-10 | Zhang Jack Y. | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 100,000 | 14.69 | 1.47M | 2,533,554 | — | ↗ |
| 2024-06-10 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 3,000 | 41.40 | 124.2K | 78,409 | — | ↗ |
| 2024-06-05 | Lee Howard | Director | F-InKind | D | Common Stock | 579 | 42.04 | 24.3K | 147,777 | — | ↗ |
| 2024-06-04 | Liawatidewi Yakob | Director / Officer | F-InKind | D | Common Stock | 272 | 42.22 | 11.5K | 74,938 | — | ↗ |
| 2024-06-03 | ZASLOFF MICHAEL A | Director | A-Award | A | Stock Option (right to buy) | 6,864 | 42.25 | 290.0K | 6,864 | — | ↗ |
| 2024-06-03 | Petersen Floyd F. | Director | A-Award | A | Common Stock | 3,076 | 0.00 | — | 81,409 | — | ↗ |
| 2024-06-03 | PRINS RICHARD K | Director | A-Award | A | Stock Option (right to buy) | 6,864 | 42.25 | 290.0K | 6,864 | — | ↗ |
| 2024-06-03 | Lee Howard | Director | A-Award | A | Stock Option (right to buy) | 6,864 | 42.25 | 290.0K | 6,864 | — | ↗ |
| 2024-06-03 | Gerst Diane G. | Director | A-Award | A | Stock Option (right to buy) | 6,864 | 42.25 | 290.0K | 6,864 | — | ↗ |
| 2024-06-03 | Deflin Gayle | Director | A-Award | A | Stock Option (right to buy) | 6,864 | 42.25 | 290.0K | 6,864 | — | ↗ |
| 2024-05-19 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 387 | 43.48 | 16.8K | 97,268 | — | ↗ |
| 2024-05-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 41.67 | 20.8K | 78,833 | — | ↗ |
| 2024-04-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 43.43 | 21.7K | 79,333 | — | ↗ |
| 2024-03-17 | Zhou Rong | Officer | F-InKind | D | Common Stock | 1,961 | 43.05 | 84.4K | 118,016 | — | ↗ |
| 2024-03-17 | Zhang Jack Y. | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 15,768 | 43.05 | 678.8K | 2,433,554 | — | ↗ |
| 2024-03-17 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 4,255 | 43.05 | 183.2K | 97,655 | — | ↗ |
| 2024-03-17 | Liawatidewi Yakob | Director / Officer | F-InKind | D | Common Stock | 1,726 | 43.05 | 74.3K | 74,778 | — | ↗ |
| 2024-03-16 | Zhou Rong | Officer | F-InKind | D | Common Srock | 2,355 | 43.05 | 101.4K | 119,977 | — | ↗ |
| 2024-03-16 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 5,105 | 43.05 | 219.8K | 101,910 | — | ↗ |
| 2024-03-16 | Liawatidewi Yakob | Director / Officer | F-InKind | D | Common Stock | 1,671 | 43.05 | 71.9K | 76,504 | — | ↗ |
| 2024-03-15 | Zhou Rong | Officer | F-InKind | D | Common Srock | 1,219 | 43.05 | 52.5K | 122,332 | — | ↗ |
| 2024-03-15 | Zhang Jack Y. | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 310,930 | 12.46 | 3.87M | 1,439,466 | — | ↗ |
| 2024-03-15 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 2,285 | 43.05 | 98.4K | 107,015 | — | ↗ |
| 2024-03-15 | Liawatidewi Yakob | Director / Officer | F-InKind | D | Common Stock | 1,027 | 43.05 | 44.2K | 78,175 | — | ↗ |
| 2024-03-06 | Zhou Rong | Officer | F-InKind | D | Common Srock | 1,390 | 46.31 | 64.4K | 123,551 | — | ↗ |
| 2024-03-06 | Zhang Jack Y. | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 2,990 | 46.31 | 138.5K | 1,128,536 | — | ↗ |
| 2024-03-06 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 2,190 | 46.31 | 101.4K | 109,300 | — | ↗ |
| 2024-03-06 | Liawatidewi Yakob | Director / Officer | F-InKind | D | Common Stock | 1,221 | 46.31 | 56.5K | 79,202 | — | ↗ |
| 2024-03-05 | ZASLOFF MICHAEL A | Director | S-Sale | D | Common Stock | 9,389 | 47.06 | 441.9K | 24,437 | — | ↗ |
| 2024-03-04 | Zhou Rong | Officer | A-Award | A | Common Srock | 12,521 | 0.00 | — | 124,941 | — | ↗ |
| 2024-03-04 | Zhang Jack Y. | Director / Officer / 10% Owner | A-Award | A | Common Stock | 64,310 | 0.00 | — | 2,143,028 | — | ↗ |
| 2024-03-04 | Liawatidewi Yakob | Director / Officer | A-Award | A | Common Stock | 10,754 | 0.00 | — | 80,423 | — | ↗ |
| 2024-03-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 451 | 45.60 | 20.6K | 79,882 | — | ↗ |
| 2024-02-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 26 | 53.64 | 1.4K | 80,333 | — | ↗ |
| 2024-01-10 | Luo Mary Z. | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 78,236 | 54.32 | 4.25M | 1,157,566 | — | ↗ |
| 2024-01-09 | Luo Mary Z. | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 3,714 | 58.35 | 216.7K | 1,235,802 | — | ↗ |
| 2024-01-08 | Luo Mary Z. | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,663 | 61.81 | 102.8K | 1,324,110 | — | ↗ |
| 2024-01-02 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 353 | 61.70 | 21.8K | 80,833 | — | ↗ |
| 2023-12-04 | Zhou Rong | Officer | M-Exempt | A | Common Stock | 3,514 | 16.19 | 56.9K | 115,934 | — | ↗ |
| 2023-12-01 | Zhou Rong | Officer | S-Sale | D | Common Stock | 4,316 | 58.58 | 252.8K | 112,420 | — | ↗ |
| 2023-12-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 135 | 57.24 | 7.7K | 81,698 | — | ↗ |
| 2023-11-17 | PRINS RICHARD K | Director | S-Sale | D | Common Stock | 4,000 | 55.86 | 223.4K | 31,895 | — | ↗ |
| 2023-11-14 | PETERS WILLIAM J | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 38,000 | 13.03 | 495.1K | 31,100 | — | ↗ |
| 2023-11-14 | Deflin Gayle | Director | S-Sale | D | Common Stock | 4,163 | 55.45 | 230.8K | 2,716 | — | ↗ |
| 2023-11-13 | PRINS RICHARD K | Director | S-Sale | D | Common Stock | 5,000 | 52.50 | 262.5K | 35,895 | — | ↗ |
| 2023-11-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 45.30 | 22.7K | 81,833 | — | ↗ |
| 2023-10-02 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 45.78 | 22.9K | 82,333 | — | ↗ |
| 2023-09-06 | PETERS WILLIAM J | Director / Officer | M-Exempt | A | Common Stock | 25,250 | 13.03 | 329.0K | 162,103 | — | ↗ |
| 2023-08-28 | Liawatidewi Yakob | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 3,319 | 16.96 | 56.3K | 0 | — | ↗ |
| 2023-08-18 | PRINS RICHARD K | Director | S-Sale | D | Common Stock | 2,000 | 52.50 | 105.0K | 40,895 | — | ↗ |
| 2023-08-15 | ZASLOFF MICHAEL A | Director | S-Sale | D | Common Stock | 12,759 | 57.22 | 730.0K | 33,826 | — | ↗ |
| 2023-08-15 | PRINS RICHARD K | Director | S-Sale | D | Common Stock | 4,163 | 57.39 | 238.9K | 42,895 | — | ↗ |
| 2023-06-20 | Zhou Rong | Officer | M-Exempt | A | Common Stock | 9,651 | 11.33 | 109.3K | 112,341 | — | ↗ |
| 2023-06-15 | Zhou Rong | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 13,575 | 14.40 | 195.5K | 4,316 | — | ↗ |
| 2023-06-15 | PETERS WILLIAM J | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 36,868 | 19.79 | 729.6K | 15,053 | — | ↗ |
| 2023-06-13 | Zhou Rong | Officer | M-Exempt | A | Common Stock | 5,000 | 14.40 | 72.0K | 93,313 | — | ↗ |
| 2023-06-10 | Lee Howard | Director | F-InKind | D | Common Stock | 375 | 45.67 | 17.1K | 145,280 | — | ↗ |
| 2023-06-05 | ZASLOFF MICHAEL A | Director | A-Award | A | Stock Option (right to buy) | 7,016 | 46.01 | 322.8K | 7,016 | — | ↗ |
| 2023-06-05 | Petersen Floyd F. | Director | A-Award | A | Common Stock | 2,716 | 0.00 | — | 82,833 | — | ↗ |
| 2023-06-05 | PRINS RICHARD K | Director | A-Award | A | Stock Option (right to buy) | 7,016 | 46.01 | 322.8K | 7,016 | — | ↗ |
| 2023-06-05 | Lee Howard | Director | A-Award | A | Common Stock | 2,716 | 0.00 | — | 145,655 | — | ↗ |
| 2023-06-05 | Gerst Diane G. | Director | A-Award | A | Stock Option (right to buy) | 7,016 | 46.01 | 322.8K | 7,016 | — | ↗ |
| 2023-06-05 | Deflin Gayle | Director | A-Award | A | Common Stock | 2,716 | 0.00 | — | 6,879 | — | ↗ |
| 2023-06-04 | Liawatidewi Yakob | Director / Officer | F-InKind | D | Common Stock | 378 | 46.70 | 17.7K | 69,669 | — | ↗ |
| 2023-06-02 | PETERS WILLIAM J | Director / Officer | M-Exempt | A | Common Stock | 11,000 | 13.35 | 146.9K | 116,603 | — | ↗ |
| 2023-06-01 | Lee Howard | Director | M-Exempt | A | Common Stock | 16,679 | 16.69 | 278.4K | 159,618 | — | ↗ |
| 2023-05-19 | PETERS WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 378 | 44.16 | 16.7K | 104,770 | — | ↗ |
| 2023-05-18 | Zhou Rong | Officer | M-Exempt | A | Common Stock | 10,000 | 14.40 | 144.0K | 97,598 | — | ↗ |
| 2023-05-18 | PETERS WILLIAM J | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 10,500 | 13.35 | 140.2K | 18,490 | — | ↗ |
| 2023-05-18 | Deflin Gayle | Director | S-Sale | D | Common Stock | 4,519 | 44.01 | 198.9K | 4,163 | — | ↗ |
| 2023-05-17 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 5,000 | 43.13 | 215.7K | 80,117 | — | ↗ |
| 2023-05-15 | ZASLOFF MICHAEL A | Director | S-Sale | D | Common Stock | 7,500 | 42.18 | 316.3K | 43,869 | — | ↗ |
| 2023-05-15 | PRINS RICHARD K | Director | M-Exempt | D | Stock option (right to buy) | 5,000 | 16.69 | 83.5K | 6,679 | — | ↗ |
| 2023-05-15 | Deflin Gayle | Director | S-Sale | D | Common Stock | 1,500 | 43.15 | 64.7K | 8,682 | — | ↗ |
| 2023-05-12 | PRINS RICHARD K | Director | M-Exempt | D | Stock option (right to buy) | 5,000 | 16.69 | 83.5K | 12 | — | ↗ |
| 2023-04-17 | PETERS WILLIAM J | Director / Officer | M-Exempt | A | Common Stock | 5,632 | 13.35 | 75.2K | 110,780 | — | ↗ |
| 2023-04-13 | PETERS WILLIAM J | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 4,868 | 13.35 | 65.0K | 34,622 | — | ↗ |
| 2023-04-13 | Liawatidewi Yakob | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 11,494 | 20.23 | 232.5K | 5,497 | — | ↗ |
| 2023-04-10 | PETERS WILLIAM J | Director / Officer | M-Exempt | A | Common Stock | 10,032 | 13.35 | 133.9K | 115,180 | — | ↗ |
| 2023-04-10 | Liawatidewi Yakob | Director / Officer | M-Exempt | A | Common Stock | 5,000 | 20.23 | 101.2K | 74,215 | — | ↗ |
| 2023-04-03 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 491 | 37.72 | 18.5K | 85,117 | — | ↗ |
| 2023-03-17 | Zhou Rong | Officer | F-InKind | D | Common Stock | 1,901 | 36.29 | 69.0K | 87,598 | — | ↗ |
| 2023-03-17 | Zhang Jack Y. | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 15,768 | 36.29 | 572.2K | 2,078,718 | — | ↗ |
| 2023-03-17 | PETERS WILLIAM J | Officer | F-InKind | D | Common Stock | 4,162 | 36.29 | 151.0K | 105,148 | — | ↗ |
| 2023-03-17 | Liawatidewi Yakob | Officer | F-InKind | D | Common Stock | 1,673 | 36.29 | 60.7K | 69,215 | — | ↗ |
| 2023-03-16 | Zhou Rong | Officer | F-InKind | D | Common Stock | 2,283 | 37.60 | 85.8K | 89,499 | — | ↗ |
| 2023-03-16 | Zhang Jack Y. | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 57,365 | 0.00 | — | 0 | — | ↗ |
| 2023-03-16 | PETERS WILLIAM J | Officer | F-InKind | D | Common Stock | 4,995 | 37.60 | 187.8K | 109,310 | — | ↗ |
| 2023-03-16 | Liawatidewi Yakob | Officer | F-InKind | D | Common Stock | 1,620 | 37.60 | 60.9K | 70,888 | — | ↗ |
| 2023-03-15 | Zhou Rong | Officer | F-InKind | D | Common Stock | 2,057 | 36.84 | 75.8K | 91,782 | — | ↗ |
| 2023-03-15 | Zhang Jack Y. | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 8,434 | 36.84 | 310.7K | 2,177,092 | — | ↗ |
| 2023-03-15 | PETERS WILLIAM J | Officer | M-Exempt | A | Common Stock | 6,688 | 14.95 | 100.0K | 131,227 | — | ↗ |
| 2023-03-15 | Liawatidewi Yakob | Officer | F-InKind | D | Common Stock | 1,851 | 36.84 | 68.2K | 72,508 | — | ↗ |
| 2023-03-06 | Zhou Rong | Officer | A-Award | A | Employee Stock Option (right to buy) | 31,882 | 35.13 | 1.12M | 31,882 | — | ↗ |
| 2023-03-06 | Zhang Jack Y. | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 171,488 | 35.13 | 6.02M | 171,488 | — | ↗ |
| 2023-03-06 | PETERS WILLIAM J | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,416 | 35.13 | 1.77M | 50,416 | — | ↗ |
| 2023-03-06 | Liawatidewi Yakob | Officer | A-Award | A | Common Stock | 12,752 | 0.00 | — | 74,359 | — | ↗ |
| 2023-03-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 1 | 33.70 | 33.70 | 86,107 | — | ↗ |
| 2023-03-01 | PETERS WILLIAM J | Officer | M-Exempt | A | Common Stock | 10,974 | 11.33 | 124.3K | 111,588 | — | ↗ |
| 2023-02-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 30.35 | 15.2K | 86,108 | — | ↗ |
| 2023-01-03 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 27.94 | 14.0K | 86,608 | — | ↗ |
| 2022-12-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 30.13 | 15.1K | 87,108 | — | ↗ |
| 2022-11-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 31.13 | 15.6K | 87,608 | — | ↗ |
| 2022-10-03 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 28.59 | 14.3K | 88,108 | — | ↗ |
| 2022-09-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 29.44 | 14.7K | 88,608 | — | ↗ |
| 2022-08-09 | PETERS WILLIAM J | Officer | S-Sale | D | Common Stock | 10,000 | 38.35 | 383.5K | 100,480 | — | ↗ |
| 2022-08-09 | Liawatidewi Yakob | Officer | M-Exempt | A | Common Stock | 3,055 | 19.79 | 60.5K | 64,662 | — | ↗ |
| 2022-08-08 | Liawatidewi Yakob | Officer | M-Exempt | A | Common Stock | 5,000 | 19.79 | 99.0K | 66,607 | — | ↗ |
| 2022-08-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 37.48 | 18.7K | 89,108 | — | ↗ |
| 2022-07-18 | Gerst Diane G. | Director | M-Exempt | D | Stock Option (right to buy) | 1,520 | 20.08 | 30.5K | 1,336 | — | ↗ |
| 2022-07-15 | Liawatidewi Yakob | Officer | M-Exempt | A | Common Stock | 10,837 | 19.79 | 214.5K | 72,444 | — | ↗ |
| 2022-07-11 | Gerst Diane G. | Director | S-Sale | D | Common Stock | 1,521 | 36.26 | 55.1K | 12,842 | — | ↗ |
| 2022-07-05 | Gerst Diane G. | Director | M-Exempt | A | Common Stock | 1,813 | 20.08 | 36.4K | 14,655 | — | ↗ |
| 2022-07-01 | Petersen Floyd F. | Director | S-Sale | D | Common Stock | 500 | 34.78 | 17.4K | 89,608 | — | ↗ |
| 2022-06-30 | PETERS WILLIAM J | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 18,386 | 0.00 | — | 6,688 | — | ↗ |
| 2022-06-30 | Gerst Diane G. | Director | M-Exempt | D | Stock Option (right to buy) | 3,333 | 20.03 | 66.8K | 3,626 | — | ↗ |
| 2022-06-17 | PETERS WILLIAM J | Officer | S-Sale | D | Common Stock | 5,512 | 32.05 | 176.7K | 100,480 | — | ↗ |
| 2022-06-14 | Liawatidewi Yakob | Officer | F-InKind | D | Common Stock | 128 | 31.02 | 4.0K | 61,607 | — | ↗ |
| 2022-06-10 | ZASLOFF MICHAEL A | Director | A-Award | A | Stock Option (right to buy) | 10,984 | 30.02 | 329.7K | 10,984 | — | ↗ |
| 2022-06-10 | Petersen Floyd F. | Director | A-Award | A | Stock Option (right to buy) | 10,984 | 30.02 | 329.7K | 10,984 | — | ↗ |
| 2022-06-10 | PRINS RICHARD K | Director | A-Award | A | Stock Option (right to buy) | 10,984 | 0.00 | — | 10,984 | — | ↗ |
| 2022-06-10 | Lee Howard | Director | A-Award | A | Stock Option (right to buy) | 10,984 | 30.02 | 329.7K | 10,984 | — | ↗ |
| 2022-06-10 | Gerst Diane G. | Director | A-Award | A | Stock Option (right to buy) | 10,984 | 30.02 | 329.7K | 10,984 | — | ↗ |
| 2022-06-10 | Deflin Gayle | Director | A-Award | A | Stock Option (right to buy) | 10,984 | 0.00 | — | 10,984 | — | ↗ |
Executive team
Top executives
EBIT / Employee
73.5K
Shares Outstanding
44.54M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jack Yongfeng Zhang Chief Executive Officer, President, Chief Scientific Officer | 950.9K | 329.7K | 3.30M | 3.30M | 361.0K | 63.7K | 8.31M | 79.48% | ↗ |
| 2 | 2025 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 775.1K | 288.9K | 1.39M | 1.39M | 128.0K | 55.0K | 4.03M | 69.06% | ↗ |
| 3 | 2025 | William J. Peters Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director | 649.8K | 370.3K | 1.04M | 1.04M | 73.0K | 57.5K | 3.24M | 64.47% | ↗ |
| 4 | 2025 | Rong Zhou Senior Executive Vice President of Production and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd | 717.6K | 280.5K | 701.5K | 701.5K | 98.0K | 43.6K | 2.54M | 55.18% | ↗ |
| 5 | 2025 | Jacob Liawatidewi Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center and President of Amphastar France Pharmaceuticals, S.A.S. | 499.9K | 265.2K | 592.0K | 592.0K | 47.0K | 41.7K | 2.04M | 58.10% | ↗ |
| 6 | 2024 | Jack Yongfeng Zhang Chief Executive Officer, President, Chief Scientific Officer | 915.3K | 317.1K | 3.00M | 3.00M | 444.0K | 54.4K | 7.73M | 77.62% | ↗ |
| 7 | 2024 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 746.0K | 314.7K | 1.27M | 1.27M | 163.0K | 43.9K | 3.80M | 66.63% | ↗ |
| 8 | 2024 | William J. Peters Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director | 625.5K | 292.6K | 907.5K | 907.5K | 121.0K | 56.7K | 2.91M | 62.35% | ↗ |
| 9 | 2024 | Rong Zhou Senior Executive Vice President of Production and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd | 564.5K | 235.1K | 584.5K | 584.5K | 116.0K | 43.4K | 2.13M | 54.94% | ↗ |
| 10 | 2024 | Jacob Liawatidewi Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center and President of Amphastar France Pharmaceuticals, S.A.S. | 480.8K | 220.4K | 502.0K | 502.0K | 75.0K | 41.6K | 1.82M | 55.11% | ↗ |
| 11 | 2023 | Jack Yongfeng Zhang Chief Executive Officer, President, Chief Scientific Officer | 898.0K | 310.8K | 2.86M | 2.86M | 736.0K | 59.9K | 7.72M | 74.04% | ↗ |
| 12 | 2023 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 732.0K | 309.6K | 1.20M | 1.21M | 280.0K | 43.0K | 3.77M | 63.85% | ↗ |
| 13 | 2023 | William J. Peters Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director | 612.6K | 283.2K | 840.5K | 840.5K | 261.0K | 55.5K | 2.89M | 58.10% | ↗ |
| 14 | 2023 | Rong Zhou Senior Executive Vice President of Production and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd | 542.3K | 209.9K | 531.5K | 531.5K | 167.0K | 43.1K | 2.03M | 52.49% | ↗ |
| 15 | 2023 | Jacob Liawatidewi Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center and President of Amphastar France Pharmaceuticals, S.A.S. | 495.5K | 195.9K | 448.0K | 448.0K | 148.0K | 40.7K | 1.78M | 50.45% | ↗ |
| 16 | 2022 | Jack Yongfeng Zhang Chief Executive Officer, President, Chief Scientific Officer | 1.11M | 293.6K | 2.67M | 2.67M | 670.0K | 56.5K | 7.48M | 71.46% | ↗ |
| 17 | 2022 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 908.0K | 309.7K | 1.13M | 1.13M | 256.0K | 56.4K | 3.78M | 59.54% | ↗ |
| 18 | 2022 | William J. Peters Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director | 584.1K | 264.1K | 764.0K | 764.0K | 222.0K | 49.0K | 2.65M | 57.72% | ↗ |
| 19 | 2022 | Rong Zhou Senior Executive Vice President of Production and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd | 463.1K | 196.3K | 474.5K | 474.5K | 134.0K | 41.7K | 1.78M | 53.19% | ↗ |
| 20 | 2022 | Rong Zhou Senior Executive Vice President of Production and President of. Amphastar Nanjing Pharmaceuticals, Co., Ltd | 463.1K | 196.3K | 474.5K | 474.5K | 134.0K | 41.7K | 1.78M | 53.19% | ↗ |
| 21 | 2022 | Jacob Liawatidewi Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center and President of Amphastar France Pharmaceuticals, S.A.S. | 440.3K | 190.9K | 400.0K | 400.0K | 123.0K | 40.0K | 1.59M | 50.18% | ↗ |
| 22 | 2021 | Jack Yongfeng Zhang Chief Executive Officer, President, Chief Scientific Officer | 898.0K | 310.8K | 2.29M | 2.29M | 673.0K | 50.6K | 6.51M | 70.31% | ↗ |
| 23 | 2021 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 732.0K | 305.6K | 1.02M | 1.02M | 259.0K | 47.8K | 3.39M | 60.36% | ↗ |
| 24 | 2021 | William J. Peters Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director | 572.1K | 261.4K | 664.4K | 664.4K | 226.0K | 52.3K | 2.44M | 54.45% | ↗ |
| 25 | 2021 | William J. Peters Chief Financial Officer, Executive Vice President of Finance, Treasurer, and President of International Medication Systems, Limited | 572.1K | 261.4K | 664.4K | 664.4K | 226.0K | 52.3K | 2.44M | 54.45% | ↗ |
| 26 | 2021 | Rong Zhou Senior Executive Vice President of Production and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd | 478.8K | 194.4K | 395.5K | 395.5K | 128.0K | 41.6K | 1.63M | 48.42% | ↗ |
| 27 | 2021 | Rong Zhou Executive Vice President of Production and President of Armstrong Pharmaceuticals, Inc. | 478.8K | 194.4K | 395.5K | 395.5K | 128.0K | 41.6K | 1.63M | 48.42% | ↗ |
| 28 | 2021 | Rong Zhou Senior Executive Vice President of Production and President of. Amphastar Nanjing Pharmaceuticals, Co., Ltd | 478.8K | 194.4K | 395.5K | 395.5K | 128.0K | 41.6K | 1.63M | 48.42% | ↗ |
| 29 | 2021 | Jacob Liawatidewi Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center and President of Amphastar France Pharmaceuticals, S.A.S. | 423.4K | 186.8K | 348.0K | 348.0K | 124.0K | 39.5K | 1.47M | 47.36% | ↗ |
| 30 | 2020 | Jason B. Shandell Former President, General Counsel and Director | 229.1K | 15.0K | 2.44M | 1.56M | — | 2.54M | 6.79M | 58.92% | ↗ |
| 31 | 2020 | Jack Yongfeng Zhang Chief Executive Officer, President, Chief Scientific Officer | 898.0K | 394.0K | 1.99M | 1.99M | 657.5K | 33.4K | 5.96M | 66.75% | ↗ |
| 32 | 2020 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 732.0K | 230.0K | 890.0K | 890.0K | 239.9K | 24.9K | 3.01M | 59.20% | ↗ |
| 33 | 2020 | William J. Peters Chief Financial Officer, Executive Vice President of Finance, Treasurer, and President of International Medication Systems, Limited | 547.5K | 297.2K | 525.0K | 525.0K | 190.0K | 54.0K | 2.14M | 49.10% | ↗ |
| 34 | 2020 | William J. Peters Chief Financial Officer, Senior Vice President of | 547.5K | 297.2K | 525.0K | 525.0K | 190.0K | 54.0K | 2.14M | 49.10% | ↗ |
| 35 | 2020 | William J. Peters Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director | 547.5K | 297.2K | 525.0K | 525.0K | 190.0K | 54.0K | 2.14M | 49.10% | ↗ |
| 36 | 2020 | Rong Zhou Senior Executive Vice President of Production and President of. Amphastar Nanjing Pharmaceuticals, Co., Ltd | 426.4K | 197.3K | 344.0K | 344.0K | 112.9K | 32.1K | 1.46M | 47.23% | ↗ |
| 37 | 2020 | Rong Zhou Executive Vice President of Production and President of Armstrong Pharmaceuticals, Inc. | 426.4K | 197.3K | 344.0K | 344.0K | 112.9K | 32.1K | 1.46M | 47.23% | ↗ |
| 38 | 2020 | Rong Zhou Executive Vice President of Production and President of Armstrong Pharmaceuticals, Inc. | 426.4K | 197.3K | 344.0K | 344.0K | 112.9K | 32.1K | 1.46M | 47.23% | ↗ |
| 39 | 2020 | Jacob Liawatidewi Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center and President of Amphastar France Pharmaceuticals, S.A.S. | 405.5K | 204.5K | 302.5K | 302.5K | 102.7K | 36.9K | 1.35M | 44.66% | ↗ |
| 40 | 2020 | Jacob Liawatidewi Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center and President of Amphastar France Pharmaceuticals, S.A.S. | 405.5K | 204.5K | 302.5K | 302.5K | 102.7K | 36.9K | 1.35M | 44.66% | ↗ |
| 41 | 2019 | Jack Yongfeng Zhang Chief Executive Officer, President, Chief Scientific Officer | 897.6K | 393.7K | 1.99M | 1.99M | 680.9K | 17.5K | 5.97M | 66.67% | ↗ |
| 42 | 2019 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 731.7K | 255.2K | 840.0K | 840.0K | 288.6K | 20.6K | 2.98M | 56.45% | ↗ |
| 43 | 2019 | Jason B. Shandell Former President, General Counsel and Director | 870.0K | 191.6K | 790.0K | 790.0K | 237.3K | 45.2K | 2.92M | 54.03% | ↗ |
| 44 | 2019 | William J. Peters Chief Financial Officer, Senior Vice President of | 528.5K | 113.9K | 525.0K | 525.0K | 223.9K | 40.6K | 1.96M | 53.65% | ↗ |
| 45 | 2019 | William J. Peters Chief Financial Officer, Executive Vice President of Finance, Treasurer, and President of International Medication Systems, Limited | 528.5K | 113.9K | 525.0K | 525.0K | 223.9K | 40.6K | 1.96M | 53.65% | ↗ |
| 46 | 2019 | William J. Peters Chief Financial Officer, Executive Vice President of Finance, Treasurer, and President of International Medication Systems, Limited | 528.5K | 113.9K | 525.0K | 525.0K | 223.9K | 40.6K | 1.96M | 53.65% | ↗ |
| 47 | 2019 | Rong Zhou Executive Vice President of Production and President of Armstrong Pharmaceuticals, Inc. | 404.5K | 151.3K | 205.0K | 205.0K | 135.9K | 32.8K | 1.13M | 36.14% | ↗ |
| 48 | 2019 | Rong Zhou Executive Vice President of Production and President of Armstrong Pharmaceuticals, Inc. | 404.5K | 151.3K | 205.0K | 205.0K | 135.9K | 32.8K | 1.13M | 36.14% | ↗ |
| 49 | 2019 | Rong Zhou Executive Vice President of Production and President of Armstrong Pharmaceuticals, Inc. | 404.5K | 151.3K | 205.0K | 205.0K | 135.9K | 32.8K | 1.13M | 36.14% | ↗ |
| 50 | 2018 | Jack Yongfeng Zhang Chief Executive Officer, President, Chief Scientific Officer | 1.09M | 338.5K | 1.94M | 1.94M | 549.9K | 14.8K | 5.87M | 66.05% | ↗ |
| 51 | 2018 | Jack Yongfeng Zhang Chief Executive Officer, Chief Scientific Officer and Director | 1.09M | 888.3K | 1.94M | 1.94M | — | 14.8K | 5.87M | 66.05% | ↗ |
| 52 | 2018 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 907.9K | 207.1K | 825.0K | 825.0K | 255.3K | 13.2K | 3.03M | 54.39% | ↗ |
| 53 | 2018 | Jason B. Shandell Former President, General Counsel and Director | 593.6K | 171.3K | 790.0K | 790.0K | 199.6K | 39.8K | 2.58M | 61.14% | ↗ |
| 54 | 2018 | Jason B. Shandell President, General Counsel and Director | 593.6K | 371.0K | 790.0K | 790.0K | — | 39.8K | 2.58M | 61.14% | ↗ |
| 55 | 2017 | Jack Yongfeng Zhang Chief Executive Officer, Chief Scientific Officer and Director | 880.0K | 668.5K | 2.09M | 2.09M | — | 27.1K | 5.76M | 72.63% | ↗ |
| 56 | 2017 | Jack Yongfeng Zhang Chief Executive Officer, President, Chief Scientific Officer | 880.0K | 296.2K | 2.09M | 2.09M | 372.3K | 27.1K | 5.76M | 72.63% | ↗ |
| 57 | 2017 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 718.0K | 203.7K | 900.0K | 900.0K | 220.8K | 13.5K | 2.96M | 60.89% | ↗ |
| 58 | 2017 | Jason B. Shandell Former President, General Counsel and Director | 574.0K | 162.8K | 850.0K | 850.0K | 149.0K | 29.1K | 2.61M | 65.01% | ↗ |
| 59 | 2017 | Jason B. Shandell President, General Counsel and Director | 574.0K | 311.8K | 850.0K | 850.0K | — | 29.1K | 2.61M | 65.01% | ↗ |
| 60 | 2016 | Jack Yongfeng Zhang Chief Executive Officer, Chief Scientific Officer and Director | 880.0K | 661.5K | 2.09M | 2.09M | — | 12.3K | 5.73M | 72.90% | ↗ |
| 61 | 2016 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 718.0K | 482.1K | 900.0K | 900.0K | — | 6.0K | 3.01M | 59.88% | ↗ |
| 62 | 2016 | Jason B. Shandell President, General Counsel and Director | 551.0K | 369.9K | 850.0K | 850.0K | — | 40.7K | 2.66M | 63.87% | ↗ |
| 63 | 2015 | Jack Yongfeng Zhang Chief Executive Officer, Chief Scientific Officer and Director | 1.22M | 795.6K | 1.87M | 1.87M | — | 51.2K | 5.81M | 64.48% | ↗ |
| 64 | 2015 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 993.9K | 502.6K | 800.0K | 800.0K | — | 30.2K | 3.13M | 51.17% | ↗ |
| 65 | 2015 | Jason B. Shandell President, General Counsel and Director | 550.7K | 385.5K | 750.0K | 750.0K | — | 17.2K | 2.45M | 61.14% | ↗ |
| 66 | 2014 | Jack Yongfeng Zhang Chief Executive Officer, Chief Scientific Officer and Director | 882.7K | 515.2K | 1.23M | 2.28M | — | 57.2K | 4.96M | 70.64% | ↗ |
| 67 | 2014 | Jack Yongfeng Zhang Chief Executive Officer, Chief Scientific Officer and Director | 882.7K | 515.2K | 2.28M | 1.23M | — | 57.2K | 4.96M | 70.64% | ↗ |
| 68 | 2014 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 719.7K | 405.6K | 535.0K | 993.0K | — | 31.3K | 2.68M | 56.92% | ↗ |
| 69 | 2014 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 719.7K | 405.6K | 993.0K | 535.0K | — | 31.3K | 2.68M | 56.92% | ↗ |
| 70 | 2014 | Jason B. Shandell President and Director | 544.0K | 307.4K | 490.0K | 910.0K | — | 22.0K | 2.27M | 61.58% | ↗ |
| 71 | 2014 | Jason B. Shandell President, General Counsel and Director | 544.0K | 307.4K | 910.0K | 490.0K | — | 22.0K | 2.27M | 61.58% | ↗ |
| 72 | 2013 | Jack Yongfeng Zhang Chief Executive Officer, Chief Scientific Officer and Director | 847.8K | 528.2K | 2.40M | — | — | 81.2K | 3.86M | 62.22% | ↗ |
| 73 | 2013 | Mary Ziping Luo Chief Operating Officer, Chief Scientist and Chairman | 671.9K | 273.8K | 1.40M | — | — | 34.1K | 2.38M | 58.83% | ↗ |
| 74 | 2013 | Jason B. Shandell President and Director | 453.4K | 245.2K | 593.0K | — | — | 23.3K | 1.71M | 34.70% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yongfeng Zhang | Co-Founder, President, Chief Executive Officer, Chief Scientific Officer & Director | 2M | — |
| Ziping Luo | Chairman of the Board, Chief Scientist & Chief Operating Officer | 1M | — |
| William J. Peters | Chief Financial Officer, Executive Vice President of Finance, Treasurer & Director | 1M | male |
| Rong Zhou | Senior EVice President of Production & EVP of Scientific Affairs | 1M | male |
| Jacob Liawatidewi | Executive Vice President of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director | 853.9K | male |
| Tony Marrs | Executive Vice President of Regulatory Affairs & Clinical Operations | — | — |
| Dan Dischner | Senior Vice President of Human Resources & Corporate Communication | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AMPH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
